

Update on the Corporate Reorganization to Consolidate the Healthcare Businesses of Bradesco Organization in Odontoprev

Banco Bradesco S.A. (B3: BBDC3, BBDC4) ("**Bradesco**"), in continuance to the Material Fact disclosed on February 27, 2026 ("**Transaction Material Fact**"), related to the consolidation of the healthcare businesses of the Bradesco Organization in Odontoprev S.A. ("**Odontoprev**" and "**Transaction**"), hereby informs its shareholders and the market in general of the following developments of the Transaction, which have occurred on the date hereof, and which follow what had already been contemplated and do not bring any changes to the Transaction.

On the date hereof:

(i) as originally contemplated in the Protocol and Justification for the Merger of Shares itself, signed on February 26, 2026, the managements of Bradesco Gestão de Saúde S.A. ("**BGS**"), Odontoprev, Bradesco and Bradseg Participações S.A. ("**Bradseg**") entered into the First Amendment to the Protocol and Justification for the Merger of Shares ("**First Amendment**"), pursuant to which, in addition to other adjustments with no impact on the terms and conditions of the Transaction (as described in the Transaction Material Fact), information arising from the appraisal report (dated March 5, 2026) of the BGS shares, at market value, was included for the purposes of determining the value of the capital increase of Odontoprev resulting from the Merger of Shares, pursuant to Articles 8 and 252 of Law no. 6,404/1976; and, as a consequence of the completion of such measures,

(ii) the Extraordinary General Shareholders' Meeting of Odontoprev was convened ("**Odontoprev EGM**"), to, in summary, resolve on: (a) the approval of the Merger of Shares (as defined in the Transaction Material Fact) of BGS by Odontoprev, including the Protocol and Justification for the Merger of Shares (as defined in the Transaction Material Fact) as amended by the First Amendment, and the respective appraisal reports; (b) the consequent capital increase of Odontoprev; (c) the amendment of Odontoprev's Bylaws, including the change of its corporate name to "Bradsaúde S.A."; and (d) the Asset Contribution (as defined in the Transaction Material Fact) to Mediservice Operadora de Planos de Saúde S.A.; all as described in the Transaction Material Fact.

Further information and the supporting documents of the Odontoprev EGM are available in the material fact notice, convening notice and management proposal disclosed by Odontoprev itself on the date hereof and made available to shareholders at Odontoprev's registered office, on its Investor Relations website (<https://ri.odontoprev.com.br>), as well as on the websites of the CVM (www.gov.br/cvm) and B3 S.A. – Brasil, Bolsa, Balcão (www.b3.com.br).

Bradesco will keep its shareholders and the market in general informed of any material developments related to the Transaction, pursuant to the applicable regulations.

Cidade de Deus, Osasco, SP, March 6, 2026.

Banco Bradesco S.A.

André Costa Carvalho
Investor Relations Officer